Login
$AVLN
$29.74 -$0.55 (1.8%) Live

$AVLN SEC Filings

Filed On Filing
12 Nov 2026 Form 4: Fmr Llc, 10% owner

Sold 175,000 shares ($5.09M) · Sold 53,454 shares ($1.61M)

12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition

Initiated Phase 1 study of AP03, a fixed dose combination of nebulized pirfenidone and nintedanib, in healthy volunteers

17 Sep 2026 Form 4: Meyer Robert J., Director

Granted 31,182 Stock Option (Right to Buy)

17 Sep 2026 Form 3: Meyer Robert J., Director

No securities owned

16 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

On September 15, 2026 (the “Effective Date”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Avalyn Pharma Inc. (the “Company”), the Board appointed Robert Meyer, M...

14 Aug 2026 SCHEDULE 13G
12 Aug 2026 10-Q
12 Aug 2026 8-K: Results of Operations and Financial Condition

Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027

11 Aug 2026 SCHEDULE 13G
06 Aug 2026 SCHEDULE 13G/A
01 Jul 2026 8-K: Entry into a Material Definitive Agreement

THIS FIRST AMENDMENT TO SUBLEASE (this “Amendment”) is made and entered into as of June 29, 2026 (the “Effective Date”), by and between CRISPR THERAPEUTICS, INC., a Delaware corporation, with a place of business at 105 West First Street,...

17 Jun 2026 8-K: Regulation FD Disclosure

Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis

03 Jun 2026 10-Q
03 Jun 2026 8-K: Results of Operations and Financial Condition

On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly presented long term open-label extension clinical data that support favorable tolerability profile

08 May 2026 SCHEDULE 13D
08 May 2026 SCHEDULE 13D
07 May 2026 SCHEDULE 13G
05 May 2026 Form 4: Novo Holdings A/S, 10% owner

Received 3,327,734 shares by conversion · Bought 555,555 shares ($10M)

05 May 2026 SCHEDULE 13G

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support